- Indivior said Monday a US court had granted rival Dr. Reddy Laboratories permission to make an emergency appeal against a preliminary injunction preventing the sale of a generic version of the Indivior's opioid addiction treatment.

The court had not yet ruled on Dr. Reddy Laboratories' motion to stay the preliminary injunction but oral argument would be held during the first week of October 2018, Indivior confirmed.

Indivior said it would continue to defend its patent rights to its opioid addiction treatment Suboxone and committed to launch its schizophrenia treatment Perseris by no later than its 1 November.

This comes as Indivior announced Monday the US Food and Drug Administration had approved Perseris.

"Clinically relevant levels were reached after the first injection of Perseris without use of a loading dose or any supplemental oral risperidone," the company said.

"Treatment adherence is a major challenge in schizophrenia due to the complexity of the disease. It is important to have additional treatment options available to physicians to help them improve their patients' symptom severity," said Maurizio Fava, Executive Vice Chair of the Massachusetts General Hospital (MGH) Department of Psychiatry and Indivior clinical research consultant.

Story provided by